A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy
of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular
carcinoma.